Clinical Interventions in Aging (Jul 2021)
Diabetic Retinopathy in the Aging Population: A Perspective of Pathogenesis and Treatment
Abstract
Sameer P Leley,1 Thomas A Ciulla,2– 4 Ashay D Bhatwadekar2 1Indiana University School of Medicine, Indianapolis, IN, USA; 2Department of Ophthalmology, Eugene and Marilyn Glick Eye Institute, Indiana University, Indianapolis, IN, USA; 3Clearside Biomedical, Inc., Alpharetta, GA, USA; 4Midwest Eye Institute, Indianapolis, IN, USACorrespondence: Ashay D BhatwadekarDepartment of Ophthalmology, Eugene and Marilyn Glick Eye Institute, 1160 W. Michigan Street, GK-305P, Indianapolis, IN, 46202, USATel +1 317-278-5075Fax +1 317-274-2277Email [email protected]: The elderly population in the United States is projected to almost double by the year 2050. In addition, the numbers of diabetics are rising, along with its most common complication, diabetic retinopathy (DR). To effectively treat DR within the elderly population, it is essential first to consider the retinal changes that occur due to aging, such as decreased blood flow, retinal thinning, and microglial changes, and understand that these changes can render the retina more vulnerable to oxidative and ischemic damage. Given these considerations, as well as the pathogenesis of DR, specific pathways could play a heightened role in DR progression in elderly patients, such as the polyol pathway and the vascular endothelial growth factor (VEGF) axis. Current ocular treatments include intravitreal corticosteroids, intravitreal anti-VEGF agents, laser photocoagulation and surgical interventions, in addition to better control of underlying diabetes with an expanding range of systemic treatments. While using therapeutics, it is also essential to consider how pharmacokinetics and pharmacodynamics change with aging; oral drug absorption can decrease, and ocular drug metabolism might affect the dosing and delivery methods. Also, elderly patients may more likely be nonadherent to their medication regimen or appointments than younger patients, and undertreatment with anti-VEGF drugs often leads to suboptimal outcomes. With a rising number of elderly DR patients, understanding how aging affects disease progression, pharmacological metabolism, and adherence are crucial to ensuring that this population receives adequate care.Keywords: diabetic retinopathy, aging, vascular endothelial growth factor, adherence, pharmacodynamic, pharmacokinetic
